CA2712965A1 - Antigen-binding polypeptides against cartilage degeneration - Google Patents

Antigen-binding polypeptides against cartilage degeneration Download PDF

Info

Publication number
CA2712965A1
CA2712965A1 CA2712965A CA2712965A CA2712965A1 CA 2712965 A1 CA2712965 A1 CA 2712965A1 CA 2712965 A CA2712965 A CA 2712965A CA 2712965 A CA2712965 A CA 2712965A CA 2712965 A1 CA2712965 A1 CA 2712965A1
Authority
CA
Canada
Prior art keywords
antigen
polypeptide
cartilage
binding polypeptide
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2712965A
Other languages
English (en)
French (fr)
Inventor
David Urech
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2712965A1 publication Critical patent/CA2712965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2712965A 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration Abandoned CA2712965A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14
PCT/CH2009/000045 WO2009097704A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Publications (1)

Publication Number Publication Date
CA2712965A1 true CA2712965A1 (en) 2009-08-13

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2712965A Abandoned CA2712965A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Country Status (10)

Country Link
US (1) US20110002927A1 (cg-RX-API-DMAC10.html)
EP (1) EP2240515A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011510667A (cg-RX-API-DMAC10.html)
CN (1) CN101939335B (cg-RX-API-DMAC10.html)
AU (1) AU2009212079B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907485A2 (cg-RX-API-DMAC10.html)
CA (1) CA2712965A1 (cg-RX-API-DMAC10.html)
IL (1) IL206720A0 (cg-RX-API-DMAC10.html)
RU (1) RU2010136988A (cg-RX-API-DMAC10.html)
WO (1) WO2009097704A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
US10143762B2 (en) 2013-12-13 2018-12-04 Mercury Assel Management Co., Ltd. Articular cartilage imaging composition
EP3452094B1 (en) * 2016-05-06 2021-11-17 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1891110A2 (en) * 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
ES2603399T3 (es) * 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales

Also Published As

Publication number Publication date
AU2009212079A1 (en) 2009-08-13
IL206720A0 (en) 2010-12-30
RU2010136988A (ru) 2012-03-20
EP2240515A1 (en) 2010-10-20
US20110002927A1 (en) 2011-01-06
JP2011510667A (ja) 2011-04-07
CN101939335B (zh) 2015-02-11
BRPI0907485A2 (pt) 2015-08-04
WO2009097704A1 (en) 2009-08-13
AU2009212079B2 (en) 2012-08-30
CN101939335A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
Kimmerling et al. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use
KR102249078B1 (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
US9304127B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
Moltó et al. Anti-IL-1 molecules: new comers and new indications
JP5022216B2 (ja) 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
US20160159900A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
AU2009212079B2 (en) Antigen-binding polypeptides against cartilage degeneration
NZ624873A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
JP2021181487A (ja) 新規な抗ｃｄ３抗体およびその使用
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
CN100500209C (zh) Clk-肽和slk-肽
KR102741829B1 (ko) 골관절염의 치료에 사용하기 위한 실데나필
CN101884784A (zh) 具有促细胞分裂活性的Bv8的核酸和多肽
WO2002070009A1 (en) Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
Adhyatmika et al. Osteoprotegerin expression in liver is induced by IL13 through TGFβ
Coll Therapeutic targeting of inflammasome signaling by blocking interleukin-1
CN119546340A (zh) 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use
CN117355323A (zh) 用于治疗骨关节炎的方法
WO2020000063A1 (en) Rheumatoid arthritis treatment
NZ624869A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
HK1088837B (en) Clk-peptide and slk-peptide
JP2002326958A (ja) 肥厚性瘢痕、ケロイドまたは慢性関節炎症性疾患予防・治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140121

FZDE Discontinued

Effective date: 20160205